DAGYNIL 1.25mg price in UAE

Overview

Welcome to Dwaey, specifically on DAGYNIL 1.25mg Tablets page.
This medicine contains an important and useful components, as it consists of Oestrogens (conjugated).
DAGYNIL 1.25mg is available in the market in concentration 1.25mg/Tablet and in the form of Tablets.

DAGRA PHARMACEUTICALS is the producer of DAGYNIL 1.25mg and it is imported from NETHERLANDS, The most popular alternatives of DAGYNIL 1.25mg are listed downward .

Mode Of Action

Acetazolamide specifically inhibits the enzyme carbonic anhydrase which catalyses the reversible reaction involving the hydration of CO2 and dehydration of carbonic acid. It increases the excretion of HCO3 ions and as well as Na and K leading to alkaline diuresis. Carbonic anhydrase is also inhibited in the CNS to retard abnormal and excessive discharge from neurons.

Indication

Glaucoma
Epilepsy
Idiopathic intracranial hypertension
Altitude sickness

Precaution

Potassium supplements may be required. Impaired hepatic or renal function; diabetes. Monitor plasma electrolytes and blood count regularly. IM route is not recommended. Caution when driving or operating machinery. Elderly. Lactation: Enters breast milk; not recommended

Side Effects

Drowsiness
paraesthesia
ataxia
dizziness
thirst
anorexia
headache; confusion
malaise
depression; GI distress
metabolic acidosis
polyuria
hyperuricaemia
renal calculi
nephrotoxicity
hepatic dysfunction. Potentially Fatal: Rarely
skin reactions or blood dyscrasias.

Contra indication

Hypersensitivity to sulphonamides; sodium or potassium depletion, hepatic insufficiency; hepatic cirrhosis; hyperchloraemic acidosis; severe renal impairment; severe pulmonary obstruction; chronic noncongestive angle-closure glaucoma; adrenocortical insufficiency. Pregnancy, lactation.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Concomitant use w/ high-dose aspirin may cause anorexia, tachypnoea, lethargy, metabolic acidosis, coma and death. May increase serum levels of phenytoin, resulting to increased risk of osteomalacia. May decrease serum concentrations of primidone. Additive effects w/ other carbonic anhydrase inhibitors. May increase the effects of folic acid antagonists. May decrease urinary excretion of amphetamine and quinidine. May prevent the urinary antiseptic effect of methenamine. May increase lithium excretion. Increased risk of renal calculus formation w/ Na bicarbonate. May increase ciclosporin levels.